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Oligodendrocyte precursor cells (OPCs) originate in speciﬁc areas of the developing central
nervous system (CNS). Once generated, they migrate towards their destinations where
they differentiate into mature oligodendrocytes. In the adult, 5–8% of all cells in the
CNS are OPCs, cells that retain the capacity to proliferate, migrate, and differentiate into
oligodendrocytes. Indeed, these endogenous OPCs react to damage in demyelinating
diseases, like multiple sclerosis (MS), representing a key element in spontaneous
remyelination. In the present work, we review the speciﬁc interactions between OPCs
and other glial cells (astrocytes, microglia) during CNS development and in the pathological
scenario of MS.We focus on: (i) the role of astrocytes in maintaining the homeostasis and
spatial distribution of different secreted cues that determine OPC proliferation, migration,
and differentiation during CNS development; (ii) the role of microglia and astrocytes in the
redistribution of iron, which is crucial for myelin synthesis during CNS development and for
myelin repair inMS; (iii) howmicroglia secrete differentmolecules, e.g., growth factors, that
favor the recruitment ofOPCs in acute phases ofMS lesions; and (iv) howastrocytesmodify
the extracellular matrix in MS lesions, affecting the ability of OPCs to attempt spontaneous
remyelination. Together, these issues demonstrate how both astroglia and microglia
inﬂuence OPCs in physiological and pathological situations, reinforcing the concept that
both development and neural repair are complex and global phenomena. Understanding
the molecular and cellular mechanisms that control OPC survival, proliferation, migration,
and differentiation during development, as well as in the mature CNS, may open new
opportunities in the search for reparative therapies in demyelinating diseases like MS.
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INTRODUCTION
Since the founding of neurosciences in the nineteenth century,
neurons, the fast excitable cells of the nervous system, have cap-
tivated the attention of almost all the successive generations of
researchers. The huge number of neurons, their fascinatingly pre-
cise interactions in the mature central nervous system (CNS), and
the diversity of physiological responses and behaviors that they
elicit, undoubtedly deserve such consideration. Nevertheless, the
number of glial cells in the CNS is close to one order of magnitude
higher than that of neurons. A recent estimate of the number of
neurons in the mature human cerebral cortex was lowered to a few
billion, being approximately sixfold more glial cells (Verkhratsky
and Butt, 2007; Kandel et al., 2013; Ribeiro et al., 2013). In the last
decade, there is even more evidence that all the major types of glial
cells fulﬁll activities beyond their classically accepted functions.
During normal adulthood and in response to pathological insults,
mature oligodendrocytes are actively replaced by oligodendrocyte
precursor cells (OPCs), a cell type that represents a highly relevant
proportion of the total cells in the adult CNS (between 5% and
8%, depending on the structure and species studied; Dawson et al.,
2000; Young et al., 2013). OPCs also receive synaptic inputs from
neurons, although the functional role of this novel interaction has
not been discovered yet (Frohlich et al., 2011; Passlick et al., 2013),
and in response to neural activity, oligodendrocytes liberate exo-
somes that offer trophic support to myelinated axons (Fruhbeis
et al., 2013).
In recent years, the amount of data indicating that both
astrocytes and microglia inﬂuences oligodendrocyte biology has
grown steadily. Far from their classic roles as physical scaf-
folds and their participation in nutrient diffusion throughout
the CNS, astrocytes have now been shown to modulate neu-
ronal activity and to respond to neurotransmitters in a clear
and excitable manner (Araque and Navarrete, 2010). In addi-
tion, the role of microglia in response to CNS injury is
now accepted to be much more complex than previously con-
sidered. Accordingly, it is becoming increasingly clear that
microglia inﬂuence homeostasis by secreting diverse molecules
that control different physiological processes, e.g., axon out-
growth, branching, inﬂammatory responses, etc. (Ransohoff
and Perry, 2009). Hence, the purpose of the present work is
to review the direct interactions between astrocytes/microglia
and OPCs during normal CNS development and in patholog-
ical circumstances, focusing particularly on multiple sclerosis
(MS).
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Oligodendrocytes were originally identiﬁed by the great
Spanish neuroscientist Pío (del Río-Hortega, 1921). They engage
in complex interactions with the soma and the axon of neurons in
the CNS, and their most singular characteristic is their ability to
form myelin sheaths (Barres and Barde, 2000). Myelin represented
a fundamental evolutionary advance given that it increases the efﬁ-
ciency and velocity of nerve impulse conduction (Zalc and Fields,
2000). Oligodendrocytes are distributed ubiquitously throughout
the adult CNS, in both the white and gray matter (Miller, 1996),
although they originate from OPCs in multiple but discrete foci
along the neural tube during development (Miller, 2002; Qi et al.,
2002; Spassky et al., 2002; de Castro et al., 2013). Once generated,
OPCs proliferate in response to different mitogenic agents and,
guided by a complex ensemble of signals, they disperse throughout
the prospective gray and white matter to populate the developing
CNS before they ﬁnally differentiate into mature oligodendro-
cytes (Rowitch, 2004; de Castro and Bribian, 2005; Furusho et al.,
2011; de Castro et al., 2013). Two different populations of OPCs
have been identiﬁed during development: (i) one type of OPC
is characterized by the expression of plp/dm-20 and these do not
depend on PDGF-AA; (ii) the second and largest population of
OPCs does depend on this growth factor and these cells express
PDGFRα (Le Bras et al., 2005). OPCs compete for both space
and trophic factors, and while ventrally generated OPCs predom-
inate in the spinal cord, those generated dorsally are the most
abundant in the telencephalic territories (Richardson et al., 2006;
Tripathi et al., 2011; de Castro et al., 2013). Once at their ﬁnal
destination, oligodendroglial cells become mature in response to
a combination of molecules (growth factors, hormones, neuro-
transmitters, extracellular matrix (ECM) proteins: Emery, 2010;
Furusho et al., 2012), and they acquire their typical biochemical
proﬁle (myelin protein expression, includingMBP,PLP, andMAG)
and morphology, covering axons and forming myelin sheaths
around them (de Castro and Zalc, 2013). During development,
many important phases of oligodendrogliogenesis and myelina-
tion are controlled by the other two main glial cells, astrocytes,
and microglia. These cells control the secretion and bioavailability
of cues or other key factors (e.g., iron) that modulate the survival,
proliferation, and migration of OPCs during the processes that
lead to the production of a functional myelin sheath. In the two
ﬁrst epigraphs of this work, the role of astrocytes and microglia
in these two important aspects will be extensively reviewed and
discussed.
Oligodendrocytes may die in different pathological scenarios,
such as primary demyelinating diseases (MS, adrenoleukodys-
trophies), traumatic and vascular accidents (spinal cord injury,
skull trauma, cerebral infarct), neurodegenerative diseases, and
schizophrenia (Edgar and Sibille, 2012; Goldman et al., 2012). The
large number of OPCs that exist in the adult brain can orchestrate
a reaction to such events, producing spontaneous remyelination
and partial recovery of the oligodendrocyte lost (Piaton et al.,
2009). The best studied demyelinating disease in humans is MS
(the most frequent neurological disease in young adults), and the
role of endogenous adult OPCs in the pathogenesis and recov-
ery of MS demyelinating lesions is currently a very active ﬁeld
of research for modern neuroscientists and neurologists (Prineas
and Parratt, 2012; Cui et al., 2013). The neuropathological events
associated with MS include the inﬁltration of blood cells into
the white matter, demyelination due to oligodendrocyte loss, and
axon degeneration (Noseworthy et al., 2000; Compston and Coles,
2008; Henderson et al., 2009). Demyelinating lesions are classiﬁed
as active, chronic-active, and chronic-inactive lesions, depend-
ing on their histopathological characteristics and their intrinsic
capability for spontaneous remyelination, which leads to the for-
mation of partially repaired shadow plaques (Table 1). Indeed,
all three types of lesion plaques can be observed in the CNS of
MS patients, independently of their clinical evolution and phe-
notype (Breij et al., 2008; Frischer et al., 2009; Bramow et al.,
2010). This implies that during the development of a demyeli-
nating lesion, not only inﬂammatory-inﬁltrated cells but also,
CNS resident astrocytes and microglia, experiment changes in
their activity and distribution thatmay affectOPCs throughdiffer-
ent mechanisms. In the third and fourth epigraphs of this review
we will summarize what is currently known about the impor-
tant effects of microglia and astroglia on OPCs in MS. We will
focus on the secretion of molecules by the resident microglia that
effectively recruits OPCs in order to replace dead oligodendro-
cytes at early (active) demyelinating lesions. We will also examine
in detail how astrocytes modify the molecular environment as
demyelinating lesions stabilize and become chronic, and their
fundamental inﬂuence on OPCs that may limit their ability to
invade the lesions or that arrests their differentiation into new
myelin-forming oligodendrocytes. Finally, we discuss how all this
knowledge could represent the basis to develop future therapeu-
tic approaches that aim to partially or totally replace the dead
oligodendrocytes.
HOW ASTROCYTES INFLUENCE OLIGODENDROCYTE
PRECURSOR CELLS DURING CNS DEVELOPMENT
During development, OPCs are generated in oligodendroglio-
genic niches that form a patchwork pattern along the neural tube,
from where they migrate to colonize the whole CNS (de Cas-
tro and Zalc, 2013). Along their complicated routes of migration,
OPCs frequently come into contact with the surface of astrocytes
and they use the astrocyte-derived matrix as a substrate for their
movement (Schnadelbach andFawcett,2001). N-cadherins are rel-
atively abundant on the surface of perinatal astrocytes and OPCs
quickly adhere to them, spreading over their surface (Schnadel-
bach et al., 2000). However, establishing long-lasting ﬁrm contacts
with astrocytes would anchor OPCs to these cells and prevent
them from migrating further (Fok-Seang et al., 1995; Schnadel-
bach et al., 2000). In addition, there is abundant evidence that
cues secreted by astrocytes inﬂuence the behavior of OPCs during
development (Barres et al., 1993; Chernausek, 1993; Gard et al.,
1995; Moore et al., 2011). Among these, PDGF-AA is one of the
best studied as its secretion by astrocytes promotes the survival
and proliferation of OPCs (Besnard et al., 1987; Raff et al., 1988;
Richardson et al., 1988; Gard et al., 1995). Indeed, the effect of
astrocyte-derived PDGF-AA in stimulating OPCs to either prolif-
erate or differentiate intomature oligodendrocytes is inﬂuenced by
the developmental stage of the progenitor cells (Raff et al., 1988),
suggesting that in the optic nerve at least, PDGF-AA produced
by astrocytes coordinates the timing of oligodendrogliogenesis
(Durand and Raff, 2000).
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Table 1 | Summary of the histopathological characteristics of the multiple sclerosis lesion.
Tissue
region
Tissue characteristics Myelin Astrocytes Microglia/macrophages Other immune cells
Active Plaque Indistinct margin;
edema;
widespread axonal damage
Demyelination;
OPC recruitment;
occasional remyelination
Hypertrophic
astrocytes;
little astrocyte
scarring
Strong microglial activation;
myelin-laden macrophages
Vascular inﬁltration of
small lymphocyte;
plasma cells
Shadow Plaque Sharply demarcated;
relative axonal preservation
≥60 % of remyelinated
area;
uniformly thin myelin
sheaths
No apparent
astrocyte
activation
No microglial activation;
absence of macrophages
Absent
Chronic-
active
Plaque Sharp edge;
hypocellular;
naked axons
Complete demyelination;
absent remyelination;
scarce OPCs
Scarring
ﬁbrous
astrocytes
Few lipid-laden
macrophages
Few inﬁltrating
leukocytes
Periplaque Initial axonal damage Demyelination;
OPC recruitment;
occasional remyelination
Hypertrophic
astrocytes
Strong microglial activation;
lipid-laden and myelin-laden
macrophages
Perivascular cuff of
inﬁltrated cells
Chronic-
inactive
(silent)
Plaque Sharp edge;
reduced number of
demyelinated axons;
thickened blood vessel wall
Complete demyelination;
absent remyelination;
scarce OPCs
Astrocytic glial
scar
Little or no microglial
activation;
reduced number of
macrophages
Occasional
leukocytes
OPC, oligodendrocyte precursor cell.
Besides the cues that promote OPC proliferation, migra-
tion, and differentiation, there are inhibitory factors that also
regulate these aspects of the oligodendrocyte biology, such as
bone morphogenetic proteins (BMPs) and chemokines. BMPs are
secreted by astrocytes (Chang et al., 2003; Miyagi et al., 2012) and
they inhibit the differentiation of OPCs into myelin-producing
oligodendrocytes (See et al., 2004; See and Grinspan, 2009). In
vitro experiments have shown that BMP4 inhibits the expression
of several myelin proteins during oligodendrocyte differentia-
tion, such as PLP and MBP (See et al., 2004). Although there
have been some in vivo studies into BMPs and oligodendro-
cyte development (Mekki-Dauriac et al., 2002; Miller et al., 2004),
the regulation of OPC differentiation by astrocyte-produced
BMPs has not yet been speciﬁcally examined. Chemokines are
another well-known example of the molecular cues expressed by
astrocytes that affects OPC behavior during development (Robin-
son et al., 1998; Tsai et al., 2002) and these molecules display
a broad range of activities in different tissues (regulation of
gene expression, cell adhesion, cell polarization, and chemo-
taxis), including the CNS (Baggiolini, 1998). During develop-
ment, oligodendrocytes express at least two chemokine receptors,
CXCR1 and CXCR2 (Nguyen and Stangel, 2001). The CXCR2
ligand, CXCL1 has been shown to promote the OPC prolifer-
ation in vitro (Robinson et al., 1998) and astrocytes transiently
express high levels of CXCL1 during the development of the
spinal cord (Tsai et al., 2002). Indeed, CXCL1-mediated signal-
ing through CXCR2 on OPCs inhibits their migration, provoking
intense proliferation by a PDGF-AA-drivenmechanism (Tsai et al.,
2002).
We recently identiﬁed another way by which astrocytes control
OPC behavior during development, by controlling the bioavail-
ability of these cues. During the ﬁrst stages of CNS development,
a gradient of Shh must be established to correctly specify the ven-
tral domains of the neural tube (Nery et al., 2001; Cohen, 2003;
Bertrand and Dahmane, 2006; Dessaud et al., 2008). Moreover,
at later developmental stages Shh participates in the prolifera-
tion and migration of OPCs during the colonization of the optic
nerve (Gao and Miller, 2006; Merchán et al., 2007). Besides the
canonical Shh receptor Patched-1 that is expressed by OPCs,
the multiligand receptor megalin, a member of the low density
lipoprotein receptor family (also known as gp330 or LRP-2), can
also bind Shh (McCarthy et al., 2002; Ortega et al., 2012). Megalin
is an important element in the molecular trafﬁcking of differ-
ent proteins within the cell and once internalized by megalin,
such proteins can be redirected, released, or hydrolyzed depend-
ing on the cell type (Christensen and Birn, 2002; McCarthy and
Argraves, 2003; Morales et al., 2006; Bento-Abreu et al., 2008).
During optic nerve development, megalin is exclusively expressed
by astrocytes, in a dynamic pattern that parallels the coloniza-
tion of OPCs from the optic chiasm to the retina (Spassky et al.,
2002; Ortega et al., 2012). When OPCs start invading the nerve,
at E14.5 in the mouse, (Spassky et al., 2002), megalin is more
profusely distributed in the caudal region of the nerve (close
to the optic chiasm) than in the rostral part (close to the eye);
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this distribution is inverted at E16.5 (megalin accumulating more
intensely near the eye) when the ﬁrst OPCs are completing their
journey to the retina. By the time OPC colonization of the
optic nerve has been completed (E18.5), megalin is weakly and
uniformly expressed all along the nerve (Ortega et al., 2012), a
time when Shh no longer attracts migrating OPCs (Merchán
et al., 2007). Moreover, in vitro experiments showed that blocking
megalin hinders optic nerveOPCproliferation andmigration, and
megalin+-astrocytes can internalize Shh for its subsequent release
at a suitable concentration (Ortega et al., 2012). Shh is homo-
geneously expressed by retinal ganglion cells and it is secreted
by their axons at different developmental stages (Traiffort et al.,
2001). Hence, megalin+-astrocytes can regulate the concentration
of extracellular Shh available in order to create a functional gra-
dient of this morphogen in the optic nerve, promoting its release
to OPCs located far from the main source (Figure 1; Ortega et al.,
2012).
In summary, most studies into oligodendrogliogenesis carried
out to date have focused on the effects exerted by different cues,
without taken into consideration the participation of other glial
cells on the diverse facets of OPC biology. However, we have given
some examples of how astrocytes regulate important aspects of
oligodendrocyte behavior through the release of several molecular
cues and by regulating their bioavailability. Hence, not only the
cue but its cellular source appear to exert an active and crucial
effect on OPCs during CNS development, which should be taken
into account in future analyses.
ASTROGLIA AND MICROGLIA REDISTRIBUTE IRON: A
CRUCIAL PROCESS FOR MYELIN SYNTHESIS DURING CNS
DEVELOPMENT AND MYELIN REPAIR IN MS
Oligodendrocytes are the main iron-containing cells in the
CNS and iron is required as a co-factor for the enzymes
involved in myelination (Todorich et al., 2009). During CNS
development, iron+-oligodendrocytes are present inmyelinogenic
foci, reﬂecting the functional relationship between iron accu-
mulation and myelin production (Connor and Menzies, 1996).
Oligodendrocytes are not able to synthesize iron, so they must
acquire it from the surrounding environment. Ferritin and trans-
ferrin are the most important proteins that deliver iron to the
brain, the latter being crucial for iron to cross the blood–brain
barrier (BBB) and enter the CNS (Leveugle et al., 1996). The brain
is the only organ in which transferrin mRNA expression augments
after birth, and this increase is directly related to oligodendrocyte
maturation. However, the expression of transferrin receptors in
oligodendrocytes decreases as the animal ages and it is not detected
in adults. For this reason, it has been suggested that ferritin acts
as an alternative iron transporter in adult oligodendrocytes and
that ferritin becomes the dominant iron delivery protein in adults
(Hulet et al., 1999).
Currently, oligodendrocytes appear to depend on two sources
of iron delivery in the brain: (i) direct transport of exogenous
ferritin/transferrin across the BBB (Fisher et al., 2007); and (ii)
resident microglial cells as a source of ferritin (Zhang et al., 2006).
During postnatal development,microglia represents themain iron
source for oligodendrocytes. It has been shown that microglia
accumulate iron just before myelination and that the decrease
in microglia iron load is paralleled by the accumulation of iron
in oligodendrocytes (Cheepsunthorn et al., 1998). These ﬁndings
suggest that microglia ﬁrst accumulate iron and that they then
release it to the developing OPCs during myelination, when the
iron requirement is maximum for their maturation (Todorich
et al., 2009). In pathological scenarios, there is compelling evi-
dence that the survival of oligodendrocytes is dependent on the
release of ferritin by microglia (Zhang et al., 2006). Recently pub-
lished in vivo data support the relevance of microglial cells as
an iron source during oligodendrocyte proliferation (Schonberg
et al., 2012). After ferritin microinjections into the spinal cord
FIGURE 1 | Schematic representation of the optic nerve trafficking of
Shh by megalin+-astrocytes. (1) RGC axons secrete Shh during optic nerve
development. (2) Shh is internalized by megalin+-astrocytes. (3) Shh is
transcytosed across the astrocytes to be released. (4) Once released, Shh
exerts its effects on Ptc-1+-expressing OPCs in the optic nerve, promoting
their migration and proliferation. RGC, retinal ganglion cells.
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of adult rats it is rapidly internalized by microglia, and then
subsequently released to promote the proliferation of NG2+-
OPCs and their differentiation into mature oligodendrocytes.
These data are consistent with the accumulation of ferritin+-NG2
cells close to an area of ferritin-expressing activated macrophages
(Schonberg and McTigue, 2009). Together, these data indicate that
in the adult CNS, microglial cells might act as a source of iron
for NG2+-cells, thereby contributing to tissue repair by stimu-
lating proliferation and the formation of new myelin-producing
oligodendrocytes.
On the other hand, most of the iron found in the human brain
parenchyma is stored as non-heme iron in oligodendrocytes and
it is essential for normal brain metabolism (Rouault and Coop-
erman, 2006). Ferrous iron ions (a liberated form of iron) must
be strictly regulated since they may generate toxic reactive oxygen
species (ROS), with oligodendrocytes being especially vulnerable
to such injury (Connor and Menzies, 1996; Todorich et al., 2009).
Indeed, abnormally high levels of iron have been detected in both
the gray and white matter of MS patients (LeVine, 1997). Since
iron can facilitate the polarization of microglia, adopting a pro-
inﬂammatory phenotype, and act as a catalyst for ROSproduction,
the liberation of the iron accumulated in the brain may partici-
pate in demyelinating and neurodegenerative processes (Williams
et al., 2012; Hametner et al., 2013). The distribution of iron differs
in MS lesions and normal-appearing white matter (NAWM), and
the oligodendrocytes located at the MS lesion edge have a reduced
iron load compared to those in the NAWM. By contrast, microglia
iron content increases in an opposite manner, i.e., it is higher
close to the periplaque than in theNAWM(Hametner et al., 2013).
This indicates a clear relationship between the exacerbation of the
pro-inﬂammatory environment and the accumulation of iron by
microglia (or macrophages) in MS tissue, as shown previously
through several in vitro and in vivo approaches (Schonberg and
McTigue, 2009; Rathore et al., 2012). The limit of this situation
lies at the innermost portion of the active lesion where extracellu-
lar iron deposits are dense and iron-containing oligodendrocytes
are shown to be damaged and disappear (Hametner et al., 2013).
Together, iron accumulation by microglia in the periplaque and
NAWMcould be understood as a bufferingmechanism to limit the
vulnerability of oligodendrocytes to oxidative damage. However,
the suggestion of enhanced pro-inﬂammatory cytokine release
by iron-loaded cultured microglia (Zhang et al., 2005) highlights
the need to understand the relationship between iron status and
oligodendrocyte damage in in vivo models of demyelination. In
summary, the role of iron in MS is a source of controversy:
while the presence of iron in lesions may increase OPC prolif-
eration and differentiation, it might also have negative effects
by promoting pro-inﬂammatory cytokine release by microglia
and the presence of a highly oxidative environment that com-
promises oligodendrocyte survival. Hence, further experiments
are needed to shed more light on how iron inﬂuences the rela-
tionship between microglia and OPCs in de- and remyelinating
scenarios.
A further twist in the complex relationship between glial cells
that controls the accumulation of iron arises when we consider
the ideal position of astrocytes to take up circulating iron and dis-
tribute it to other cells via the iron exporter, ferroportin (Jeong and
David, 2003). Indeed, the induction of toxin-driven demyelination
in an astrocyte-speciﬁc ferroportin knockout mouse produces a
clear decrease in the rate of remyelinationdue to reducedOPCpro-
liferation (Schulz et al., 2012). It was suggested that thismay reﬂect
a direct effect of iron on OPCs (direct iron deﬁciency in this cell
type) or an indirect effect of iron deprivation in microglial cells.
Iron deprivation would affect the activation state of microglia,
reducing the secretion of pro-inﬂammatory cytokines and recip-
rocally down-modulating the production by astrocytes of growth
factors involved in OPC proliferation (IGF-1 and FGF-2). Hence,
there is clearly a need for more detailed research in this area in
order tounderstand the true role of ironhomeostasis in the biology
of all glial cell types, and its consequences in diverse pathological
scenarios, including MS.
MICROGLIA INDUCE THE PROLIFERATION AND
RECRUITMENT OF OPCs IN EARLY MS LESIONS
MICROGLIAL PHENOTYPES AS REGULATORS OF THE INFLAMMATORY
ENVIRONMENT IN MS
It is becoming more established that the regeneration
observed in MS lesions, i.e., remyelination, may be a
consequence of changes in the local environmental equi-
librium between pro-inﬂammatory/pro-myelin-damage and
anti-inﬂammatory/pro-regenerative molecules/cells (Rawji and
Yong, 2013). Fundamental components of this functional switch
are the cells of the innate immune system, mainly CNS-
resident microglia and their peripherally derived counterparts,
macrophages. Microglia are important elements in the innate
immune system that are located within the CNS, and that inﬂu-
ence the adaptive immune response and the biological activities of
other resident CNS cells (Ransohoff and Perry, 2009). Classically,
microglia (and macrophages) have been exclusively considered in
a negative light in MS, based on their capacity to secrete toxic
molecules and present antigens to cytotoxic lymphocytes (Banati
et al., 1993; Cash et al., 1993). In recent years, it has been shown
that activated microglia probably facilitate remyelination in MS
and for example, phagocytosis of myelin debris is necessary for
complete remyelination (Li et al., 2005; Kotter et al., 2006; Setzu
et al., 2006). In addition, regenerative microglia/macrophages
enhance growth and neurotrophic factor production (Kotter et al.,
2005; Clemente et al., 2011). Although controversial (Block et al.,
2007; Hanisch and Kettenmann, 2007), recent data suggest that
microglia can fulﬁll both roles, showing physiologically different
phenotypes as regulators of degenerative or regenerative processes
(Miron et al., 2013). This clearly indicates the existence of at least
two activated states of microglia and macrophages: (i) the classical
activated state orM1, that is associatedwith enhanced antigen pre-
sentation and the secretion of pro-inﬂammatory cytokines, as well
as reactive oxygen and nitrogen species (Edwards et al., 2006); and,
(ii) the alternative/de-activating M2 polarized phenotype, which
secretes anti-inﬂammatory cytokines and growth factors, that par-
ticipates in tissue regeneration by limiting inﬂammation, and
that also induces OPC recruitment, proliferation, and differentia-
tion (Edwards et al., 2006; Miron et al., 2013). Signiﬁcantly, both
fetal and adult isolated human microglia and macrophages have
recently been shown to polarize to aM1/M2 phenotype depending
on the local environment they are cultured in (Durafourt et al.,
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2013). It is important to note that the molecules that M1 and
M2 cells secrete reciprocally control their activated states in the
CNS, in what represents a clear example of a homeostatic equi-
librium aimed at controlling tissue damage (Das et al., 2001; Jang
et al., 2013). Moreover, it has been demonstrated that both acti-
vated residentmicroglia and inﬁltrated activatedmacrophages can
switch dynamically from an M1 to a M2 phenotype in a demyeli-
nating environment in vivo and in vitro (Miron et al., 2013). In this
sense, growth factor secretion is suppressed in a pro-inﬂammatory
(M1) environment but it is encouraged in aM2 anti-inﬂammatory
scenario, with ﬁne reciprocal control (Wynes and Riches, 2003).
Therefore, a disturbed balance among interacting growth fac-
tors that regulate OPC proliferation, migration, differentiation,
and hence, the onset of myelin formation, may contribute to the
limited remyelination observed in MS lesions (Figure 2).
FACTORS SECRETED BY MICROGLIA AND THEIR INFLUENCE ON
ENDOGENOUS REMYELINATION
IGF-1 is one of the growth factors that has been studied
most extensively in the CNS, being produced putatively by M2
microglia/macrophages to promote myelin repair. It enhances the
survival of oligodendrocytes, promotes oligodendrocyte develop-
ment, and stimulates the synthesis of myelin (McMorris et al.,
1986; Barres et al., 1992; Roth et al., 1995; Mason et al., 2000). It is
likely that IGF-I acts through IGF-receptor 1 (IGFR1) on the sur-
face of cells of the oligodendrocyte lineage, sinceOPCproliferation
is diminished and apoptosis is enhanced in an IGFR1 conditional
knockoutmice for this lineage, resulting in fewermature oligoden-
drocytes (Zeger et al., 2007). IGF-1 not only protects myelin from
different types of insults (Cao et al., 2003; Wood et al., 2007) but
also, it is known to promote oligodendrocyte proliferation and dif-
ferentiation from multipotent precursor cells (Mason et al., 2000;
Hsieh and Papaconstantinou, 2004). After cuprizone-induced
demyelination, the lack of IGF-1 in an IL-1β knockout mice paral-
lels the delay in OPC differentiation into mature oligodendrocytes
(Mason et al., 2001), whereas its overexpression promotes remyeli-
nation by enhancing the survival of myelinating oligodendrocytes
(Mason et al., 2000). In several toxin-induced models of demyeli-
nation, IGF-1 is up-regulated in microglial cells during the stages
of myelin loss, peaking at the end of the demyelination period
when the ﬁrst remyelinating proﬁles appear (Hinks and Franklin,
1999; Fushimi and Shirabe, 2004; Gudi et al., 2011; Voss et al.,
2012). By contrast, in MS tissue IGF-1 was ﬁrst detected in hyper-
trophic astrocytes but not in macrophages or microglia within
active lesions, and its receptor IGFR1wasobserved inmacrophages
and in a subpopulation of astrocytes, yet not in oligodendrocytes
within plaques (Gveric et al., 1999). Subsequently, both IGF-1 and
IGFR1 were found in oligodendrocytes at the edge of chronic
lesions, as well as in the NAWM, albeit expressed much more
strongly in the former (Wilczak et al., 2008). Therefore, the data
from animal models and human tissue differ, which may reﬂect
the simplicity of a weakly stimulated immune system model (i.e.,
toxin-induced), and the complexity of different cells and processes
detected in the human MS tissue.
Among the growth factors studied to date, FGF-2 is consid-
ered to be one of the most controversial in terms of myelin repair.
Undoubtedly, FGF-2 is one of the main mitogens for OPCs and
it participates as a motogenic/chemokinetic and chemotropic fac-
tor for OPC migration during development (Bogler et al., 1990;
McKinnon et al., 1990; Bribián et al., 2006), a property that it
retains in adulthood (Clemente et al., 2011). This latter activ-
ity is mediated by its binding to FGFR1, which is expressed by
both embryonic and adult OPCs (Bansal et al., 1996; Bribián
et al., 2006; Clemente et al., 2011). However, other effects of
FGF-2 on oligodendroglial cells have been questioned, i.e., dif-
ferentiation. The ﬁrst reports indicated that FGF-2 arrests OPC
differentiation in vitro in normal or pseudo-pathological condi-
tions (Goddard et al., 1999, 2001). However, following the deletion
of both fgfr1/fgfr2 in the oligodendrocyte lineage, it appears that
FGF signaling is required for correctmyelinationwithout affecting
oligodendrocyte proliferation (Furusho et al., 2012). Thus, FGF-2
may be involved speciﬁcally in oligodendrocyte responses during
demyelination and remyelination. However, this growth factor
has controversial effects during regenerative processes in differ-
ent demyelinating animal models with no or low interference
of immune response (Armstrong et al., 2002; Butt and Dinsdale,
2005; Tobin et al., 2011). By contrast, it seems that in the immune-
associated demyelinating model EAE, FGF-2 controls the immune
system response and cell inﬁltration, which provokes a protec-
tive oligodendrocyte effect (Rufﬁni et al., 2001; Rottlaender et al.,
2011). Hence, FGF-2 would be another putative candidate to
ﬁne tune the regulation of the M1/M2 phenotype in complex
autoimmune demyelinating diseases, like MS.
The source of FGF-2 varies in function of the demyelinat-
ing models explored. Enhanced expression of this growth factor
was detected in microglial cells within spinal cord lesions due to
lysolecithin-induced demyelination (Hinks and Franklin, 1999),
and in the corpus callosum of cuprizone-induced demyelinat-
ing lesions at the time when remyelination starts (Gudi et al.,
2011). Conversely, FGF-2 was found in astrocytes after a hep-
atitis virus-induced demyelination in mice (Messersmith et al.,
2000), whereas in EAE, FGF-2 was mainly described in microglia
and macrophages associated with demyelinated areas (Liu et al.,
1998).We recently shed some light on the controversial adscription
of the cell source of this growth factor by describing the pat-
tern of FGF-2 expression in different MS lesions (Clemente et al.,
2011). Although almost absent in control subjects, FGF-2 was
detected in a subpopulation of CD68+HLA-DR+-macrophages
or microglia within active lesions and in the periplaque of
chronic-active lesions, both areas where remyelination occurs
spontaneously (Frohman et al., 2006). Interestingly, FGF-2 almost
disappeared from partially remyelinated shadow plaques, with
no differences between the NAWM and the remyelinated area
in terms of the distribution and shape of the scarce FGF-2-
containing microglial cells. It is particularly interesting that those
areas where remyelination is compromised (the core of chronic
lesions) are devoid of FGF-2-producing cells (Clemente et al.,
2011). Therefore, a clear parallel exists between the spontaneous
remyelination associated with a speciﬁc lesion and the presence
of FGF in macrophage/microglial cells. Identifying the elements
controlling the M1/M2 characteristics of the FGF-2 expressing
macrophages/microglia, as well as those involved in establishing
their resident-microglial or inﬁltrating-macrophage origin, will
require further analysis.
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FIGURE 2 | Schematic drawings of the different types of lesions in the
MS white matter. M1 active lesions are characterized by the presence of
microglia/macrophage in a pro-inﬂammatory activity state. In these lesions,
remyelination does not occur and demyelination advances. According to the
results observed in a murine model of focal demyelination (Miron et al., 2013),
an active lesion may derive into a M2 predominant activity state and thus,
microglia/macrophages would change their phenotype and begin to release
pro-regenerative molecules, such as the growth factors IGF-1 or FGF-2. If this
activity persists, partial remyelination may exist in the so-called shadow
plaque. By contrast, if the myelin-destructing environment takes hold, an
active lesion may evolve into a chronic-active lesion in which remyelination
can mainly occur in the periplaque (with M2 microglia/macrophage growth
factor release) whereas the plaque is devoid of remyelinating proﬁles due, in
part, to the blockade of OPC invasion and differentiation provoked by unusual
astroglial ECM deposition. In chronic-inactive lesions, inﬂammatory and
demyelinating activity ceases in both areas.
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Interestingly, we revealed a gradient in the density of FGFR1
expressing PDGFRα-OPCs in human tissue for the ﬁrst time,
from more numerous within areas where FGF-2-expressing
macrophages were present to rare in the adjacent NAWM
(Clemente et al., 2011). This observation, together with the afore-
mentioned conservation of the chemoattractant capacity of FGF-2
on adult OPCs (Clemente et al., 2011), represents one of the ﬁrst
examples in human of the interesting relationship between puta-
tiveM2 regenerativemacrophages/microglia and reparativeOPCs,
exclusively in those areas where remyelination may occur. Indeed,
FGFR1 up-regulation on OPCs may be due to FGF-2 itself (Bansal
et al., 1996), or it may be the result of the existence of two differ-
ent subpopulations of FGFR1+- and FGFR1−-OPCs with speciﬁc
proliferative, migratory and/or differentiating responses to this
growth factor. All these considerations should be carefully taken
into account in order to design new growth factor strategies to
treat a complex disease like MS.
ASTROCYTES MODIFY THE EXTRACELLULAR MATRIX IN
ADVANCED MS LESIONS, AFFECTING SPONTANEOUS
REMYELINATION
As mentioned above, spontaneous remyelination associated
with active MS lesions is possible under speciﬁc circumstances
(Frohman et al., 2006; Patrikios et al., 2006; Patani et al., 2007).
However, in chronic MS lesions remyelination is absent or mainly
detected in the plaque border (Prineas and Connell, 1979; Barkhof
et al., 2003; Bramow et al., 2010), probably due to the blockade of
OPC migration into this area or to the arrest of their differenti-
ation once they invade it (Franklin and Ffrench-Constant, 2008;
Kuhlmann et al., 2008; Clemente et al., 2011). This implies com-
plex changes in the lesion environment, e.g., in the ECM, mainly
due to alterations in the astrocyte secretion proﬁle (Sobel and
Mitchell, 1989; Gutowski et al., 1999; Back et al., 2005;VanHorssen
et al., 2005, 2006; Satoh et al., 2009).
The ECM is the ground substrate found in the interstitial
spaces of all organs that provides support to its cells. In the CNS,
the ECM is secreted by different cell types, including astrocytes,
and it has traditionally been considered to play a predominantly
structural role. However, recently new characteristics of the ECM
have emerged and it has been shown that the composition of
the ECM is strongly modiﬁed in MS, affecting both parenchy-
mal and basement membrane components (Van Horssen et al.,
2005, 2006). Several studies have considered how the astrocyte-
secreted ECM inﬂuences the behavior of OPCs in MS (Maier et al.,
2005; Clemente et al., 2011). Changes in the composition of the
ECM due to astrocyte secretion during the evolution of a given
lesion may convert a permissive environment for myelin repair
into an inhibitory area, depending on the protein composition
and the receptors expressed by the OPCs (de Castro et al., 2013).
Nonetheless, in many cases, the role of different protein compo-
nents of theECMhas been studied separately in both glial cell types
(the responder OPC or the producer, mainly astrocytes), or only
partially in the different aspects of oligodendroglial development
(proliferation, migration, differentiation), without analyzing the
consequences or the relationship between both cell types.
The ﬁrst in vitro evidence of such a tight relationship came
more than 10 years ago (Schnadelbach et al., 2000; Maier et al.,
2005). Subsequently, the progressive death of mouse oligodendro-
cytes in culture was shown to be suppressed by laminin-containing
astrocytes through a mechanism that was dependent on the inte-
grin receptor composition of the OPC cell membrane (Corley
et al., 2001). Oligodendrocyte loss and microglial activation with-
out strong participation of the immune system occurs in the
cuprizone demyelination model (Matsushima and Morell, 2001),
making it a good model to characterize the astroglial response
during demyelination/remyelination. In this model, astrocytes
exhibit stronger expression of ﬁbronectin and chondroitin sul-
fate proteoglycans (CSPGs) with a dense elaboration of GFAP-
and vimentin-containing processes (Hibbits et al., 2012). Similar
changes in ECM composition have been obtained in the Theiler’s
virus murine model of encephalomyelitis (TMEV), involving an
accumulation of CSPGs (decorin and neurocan), glycoproteins
(laminin, entactin, tenascin-C, and ﬁbronectin) and collagens
(I and IV), paralleling the spatial and temporal development of
astrogliosis within the demyelinated areas of the spinal cord (Haist
et al., 2012).
CHONDROITIN SULFATE PROTEOGLYCANS
CSPGs are a large family of ECM macromolecules, composed of a
central core protein to which varying numbers of glycosamino-
glycan side chains are attached. These proteins are expressed
ubiquitously throughout the CNS and they fulﬁll critical roles
in CNS development, plasticity, and post-injury responses (Laabs
et al., 2007), as well as inhibiting the outgrowth of OPC processes,
OPC differentiation, and adhesion (Siebert and Osterhout, 2011).
Surprisingly, there is little information regarding the source of
these macromolecules in both animal models and MS tissue. In
MS lesions, there are fewer CSPGs in active lesions due to the
action of myelin-phagocytosing foamy macrophages (Sobel and
Ahmed, 2001). By contrast, in the lysolecithin-induced demyeli-
nation model CSPGs are over expressed in microglial cells in the
core, and in astrocytes at the border of the demyelinated areas,
indicating that CSPGs can probably be deposited by different cell
types (Lau et al., 2012). Hyaluronan is a specialized glycosamino-
glycan that binds CSPGs and this molecule is a paradigmatic
example of the changes in ECM content during the evolution
of a demyelinating area in EAE. Hyaluronan is secreted in a
low molecular weight form by lymphocytes and macrophages in
early lesions, while it is deposited in a higher molecular weight
form by activated astrocytes in aged lesions. In MS tissue, the
high molecular weight form is mainly detected at the core of
chronic lesions, which is not as permissive to remyelination as
the core (Back et al., 2005). It was suggested that in chronic
demyelinated lesions, astrocyte-derived hyaluronan may inhibit
OPC maturation, thereby blocking remyelination (Back et al.,
2005). In this model the mechanism controlling failed remyeli-
nation in MS involves hyaluronan degradation by hyaluronidases,
which generate hyaluronan oligomers that block OPC maturation
and remyelination through TLR2-MyD88 signaling (Sloane et al.,
2010).
In recent years, further insight into the inﬂuence of CSPGs
and CSPG-related molecules on remyelination has opened excit-
ing perspectives, given that the speciﬁc branching of CSPGs also
appears to control OPC differentiation towards myelin-producing
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cells. Glycans, the complex molecules that are made up of sugar
chains of varying lengths, are gaining importance in neural
cell interactions during demyelination. In the cuprizone model,
N-acetylglucosaminyltransferase-IX (GnT-IX) and therefore, the
presence of branched O-mannosyl glycans on astrocytes, impeded
OPC differentiation and therefore, reduced the remyelination rate
(Kanekiyo et al., 2013).
FIBRONECTIN
Another fundamental component of the ECM is ﬁbronectin (Stof-
fels et al., 2013b), which has been implicated in OPC migration
in vitro and in vivo (Sheppard et al., 1991; Milner et al., 1996),
possibly preventing premature fetal myelin formation rather than
participating in myelin formation per se (Buttery and Ffrench-
Constant, 1999). In recent years, growing evidence indicate that
ﬁbronectin may inhibit the outgrowth of oligodendrocyte pro-
cesses and myelin sheath formation in the white matter (Siskova
et al., 2009), and that aggregated ﬁbronectin inhibits myelin
formation in different experimental paradigms (Stoffels et al.,
2013a,b). As ﬁbronectin is not expressed in the CNS of healthy
adult humans, its presence in lesions may interfere with OPC dif-
ferentiation, thereby impairing remyelination. In MS, ﬁbronectin
rapidly accumulates as an acute response to demyelination,
although it is broken down during remyelination. However, in
chronic lesions, astrocyte-released aggregated ﬁbronectin persists
(Stoffels et al., 2013a). Interestingly, cultured astrocytes produce
ﬁbronectin in a diffuse pattern in standard conditions, whereas it
is deposited in ﬁbril-like structures in inﬂammatory conditions.
This explains why ﬁbronectin transiently appears in a soluble state
in demyelinated areas of the lysolecithin infusionmodel, while ﬁlls
the inﬁltrated area in an aggregated form in the chronic relapsing
EAE MS model (Stoffels et al., 2013a). Like many other ECM pro-
teins, ﬁbronectin binds integrins, an important family of receptors
present in many cell types, including oligodendrocytes, that ful-
ﬁll important roles in CNS myelination during development and
in adulthood (for reviews on this topic see O’Meara et al., 2011;
Ahrendsen and Macklin, 2013).
ANOSMIN-1
We have studied the role of anosmin-1 in OPC development,
another component of the ECM that is defective in the X-linked
form of Kallmann syndrome (Soussi-Yanicostas et al., 2002; Dode
andHardelin, 2009). During development, anosmin-1 is expressed
by both astrocytes and oligodendrocytes of diverse nerves and
tracts in the CNS (Clemente et al., 2008; Gianola et al., 2009),
as well as in axonal bundles at the time when OPCs colonize
them (Bribián et al., 2006, 2008). During CNS development,
anosmin-1 partially blocks the motogenic effect of FGF-2 on
OPCs, a role that is conserved throughout lifespan. These effects
were demonstrated to be FGFR1-dependent (Bribián et al., 2006;
Clemente et al., 2011). Anosmin-1 participates in OPC adhesion
in a manner that is independent of FGF-2 (Bribián et al., 2008),
its different structural domains interacting with several other
ECM proteins, including anosmin-1 itself (Bribián et al., 2008;
Murcia-Belmonte et al., 2010). Although the cellular source of
anosmin-1 has proven difﬁcult to deﬁne in human tissue (Lutz
et al., 1994; Duke et al., 1995), it may be synthesized by astrocytes,
as occurs during the development of the cerebellum (Gianola
et al., 2009). In MS, anosmin-1 is absent from active lesions or
shadow plaques (i.e., areas where remyelination occurs), whereas
it is found in the core of chronic-active and chronic-inactive
plaques (areas where remyelination is compromised: Clemente
et al., 2008). The presence of anosmin-1 in chronic MS plaques
may impede OPC colonization rather than inhibit their differen-
tiation. The effects of anosmin-1 on adult human OPCs in MS
may be governed by FGFR1, since this receptor is up-regulated in
this cell type in the periplaque of chronic lesions, while is not
present within chronic lesions (Clemente et al., 2011). Indeed,
this may be one of the reasons OPC colonization of this spe-
ciﬁc region is obstructed in humans, thereby blocking axonal
remyelination.
In the past few years, the inﬂuence of ECM content on the
shape of oligodendrocytes has become evident and it was shown
that the surface area of this cell type critically depends on acto-
myosin contractility, which is regulated by the physical properties
of the supporting matrix (Kippert et al., 2009). It was also demon-
strated that the presence of astrocyte-producedECMproteinswith
non-permissive growth properties in the CNS blocks oligoden-
drocyte surface spreading, which is accompanied by changes in
the rate of endocytosis (Kippert et al., 2009). One implication of
these ﬁndings would be that changes in the rigidity of the scarred
MS lesion, an effect of the proteins secreted by reactive astrocytes,
may shift the balance of the intracellular and extracellular forces,
thereby inhibiting oligodendrocyte differentiation. Thus, the pres-
ence or persistence of an ECM protein in the core of chronic
MS lesions could cause an increase in the rigidity of the demyeli-
nated area compared to the surrounded periplaque, producing
changes in the cellular forces that might drive the inhibition of
remyelination. Another possibility that has been unexplored to
date, is that, although these extracellular cues might not alter
the physical properties of the demyelinated area, they would
change the activity of signaling molecules that regulate intra-
cellular forces (speciﬁcally those related to RhoA), thereby also
inhibiting remyelination (Bauer and Ffrench-Constant, 2009; Baer
et al., 2009). Anosmin-1 would be a ﬁrm candidate to mediate this
phenomenon since it induces cytoskeletal rearrangements through
FGFR1-dependent mechanisms involving Cdc42/Rac1 activation,
two members of the Rho family of small GTPases (González-
Martínez et al., 2004). However, further experiments are needed
to establish whether anosmin-1 participates in controlling acto-
myosin contractility and thus, oligodendrocyte cell shape and
differentiation.
CONCLUDING REMARKS
Oneof themost fundamental questions in neuroscience is whether
it is possible to resolve pathological questions by recapitulat-
ing data obtained during the analysis of the CNS development.
In this review we describe how microglia and astrocytes estab-
lish different interactions with OPCs, both in the normal CNS
and in pathological conditions (a summary is described in
Figure 3). Different astrocyte-secreted cues during development
(semaphorins, Shh, FGF-2) inﬂuence the behavior of OPCs, either
directly or indirectly, driving the response to important signals
and/or helping to generate their gradients in vivo. Moreover,
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FIGURE 3 | Schematic representation of glia-glia interactions during
development and pathology. Myelination is the result of a well
orchestrated variety of processes affecting OPC biology (several of them are
summarized on the blue shadow). During development, astrocytes and
microglia release several molecules (in green) which controls diverse aspects
of the oligodendrogliogenesis. Both astrocytes and microglia are able to turn
into an activated state in pathological conditions, such as MS. These activated
cells can produce molecular factors (purple), which exert their effects on adult
OPCs, enhancing (arrows) or impairing (bars) all the processes related to
myelin synthesis and repair.
controlling iron homeostasis by microglia and astrocytes is not
only essential for OPCs during normal myelination (Todorich
et al., 2009) but also, in pathological circumstances (Williams
et al., 2012). The overproduction of developmental growth factors
by microglia/macrophages in areas where remyelination succeeds
(Clemente et al., 2011) seems to be crucial for myelin sheath
repair. This microglia–OPC interaction may represent a promis-
ing way to enhance the endogenous capacity to replace dead
oligodendrocytes. Conversely, de novo deposition of different
adhesion molecules by astrocytes in regions where remyelination
does not spontaneously occur (Sobel and Mitchell, 1989; Back
et al., 2005; Clemente et al., 2011; Stoffels et al., 2013a) could be
interpreted as returning to a general developmental program to
protect neural cells from extensive damage with non-desirable
consequence for OPCs: the arrest of their migration and dif-
ferentiation that impairs myelin repair. Hence, further studies
about OPC biology should address: (i) the effects of the dif-
ferent molecules important for oligodendrogliogenesis during
development (ECM proteins, secreted growth factors, secreted
chemotropic molecules) on the biology of adult OPCs; (ii)
the potential beneﬁts of microglia as biological pumps for the
in situ release of molecules that could reinforce myelin repair;
(iii) the consequences of functionally silencing the signaling
pathways in astrocytes that represent an obstacle for neuropro-
tection and remyelination in chronic MS lesions. In this sense,
current MS therapies hinge on the supposition that control-
ling the inﬂammatory response will not only limit cell damage
by inactivating different components of the innate or adaptive
immune system, but that it will also have positive consequences
on neuro-repair. However, the latter hypothesis has yet to be
studied in MS tissue. Thus, it would be important to assess the
speciﬁc effects of immunoregulatory molecules on the behavior
of adult human OPCs and moreover, the effect of these current
MS treatments on microglia and astrocytes, now clearly estab-
lished as crucial partners in all the biological processes involved in
OPC development: proliferation, migration, differentiation, and
survival.
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